Have a personal or library account? Click to login
Anticardiolipin Antibodies in COVID-19 – Report of Three Cases Cover

Anticardiolipin Antibodies in COVID-19 – Report of Three Cases

Open Access
|Mar 2021

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is prone to thrombotic events with pathogenic mechanism that are still incompletely understood. Occurrence of antiphospholipid antibodies, especially anticardiolipin antibodies, was described in many viral infections and could be part of the chain in micro-thrombosis occurrence in COVID-19. We herein present three cases of COVID-19 patients without any known immune background. For two of the patients, the laboratory tests show neither inflammatory syndrome, nor elevated D-dimer. Even if pauci-symptomatic patients, pulmonary involvement in as much as 10 - 25% was identified on chest computer tomography exam. In addition, a third patient, with more important pulmonary involvement (25-50%), inflammatory response and elevated D-dimer levels is presented. None of the patients had prolonged activated partial-thromboplastin time. IgM and/ or IgG anticardiolipin antibodies were found positives in all three cases.

DOI: https://doi.org/10.2478/inmed-2021-0151 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818
Language: English
Page range: 59 - 67
Published on: Mar 13, 2021
Published by: Romanian Society of Internal Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Alina Dima, Ruxandra Valentina Moroti, Daniela Nicoleta Popescu, Ioana Berza, Delia Adriana Pârvu, Bianca Dumitrescu, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.